PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF)
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000975544.01102.10 |
| _version_ | 1797281522637602816 |
|---|---|
| author | Francesca Palandri Stefanie Gröpper Michael Loschi Marcelo Bellesso Sebastian Grosicki Pilar Giraldo Claire Harrison Tracy Clevenger Nikki Stuart Hope Qamoos Gregory Vosganian Wayne P. Rothbaum Srdan Verstovsek Pankit Vachhani |
| author_facet | Francesca Palandri Stefanie Gröpper Michael Loschi Marcelo Bellesso Sebastian Grosicki Pilar Giraldo Claire Harrison Tracy Clevenger Nikki Stuart Hope Qamoos Gregory Vosganian Wayne P. Rothbaum Srdan Verstovsek Pankit Vachhani |
| author_sort | Francesca Palandri |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:58:43Z |
| format | Article |
| id | doaj.art-2015dc24d2b0468881ed8e663ddade56 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:58:43Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-2015dc24d2b0468881ed8e663ddade562024-03-03T03:25:47ZengWileyHemaSphere2572-92412023-08-017e011021010.1097/01.HS9.0000975544.01102.10202308003-02060PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF)Francesca Palandri0Stefanie Gröpper1Michael Loschi2Marcelo Bellesso3Sebastian Grosicki4Pilar Giraldo5Claire Harrison6Tracy Clevenger7Nikki Stuart8Hope Qamoos9Gregory Vosganian10Wayne P. Rothbaum11Srdan Verstovsek12Pankit Vachhani131 IRCCS S. Orsola-Malpighi, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy2 Marien Hospital Duesseldorf, Duesseldorf, Germany3 Centre Hospitalier Universitaire (CHU) de Nice - Hopital L’Archet II, Nice, France4 IEP - Instituto de Ensino e Pesquisa Sao Lucas, São Paulo, Brazil5 Medical University of Silesia, Department of Hematology and Cancer Prevention, Katowice, Poland6 Hospital Quironsalud de Zaragoza, Zaragoza, Spain7 Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom8 Telios Pharma, Inc., Redwood City, United States8 Telios Pharma, Inc., Redwood City, United States8 Telios Pharma, Inc., Redwood City, United States8 Telios Pharma, Inc., Redwood City, United States8 Telios Pharma, Inc., Redwood City, United States9 The University of Texas MD Anderson Cancer Center, Houston, United States10 University of Alabama at Birmingham, Birmingham, United Stateshttp://journals.lww.com/10.1097/01.HS9.0000975544.01102.10 |
| spellingShingle | Francesca Palandri Stefanie Gröpper Michael Loschi Marcelo Bellesso Sebastian Grosicki Pilar Giraldo Claire Harrison Tracy Clevenger Nikki Stuart Hope Qamoos Gregory Vosganian Wayne P. Rothbaum Srdan Verstovsek Pankit Vachhani PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF) HemaSphere |
| title | PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF) |
| title_full | PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF) |
| title_fullStr | PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF) |
| title_full_unstemmed | PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF) |
| title_short | PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF) |
| title_sort | pb2198 trial in progress an open label global multicenter phase 1b 2 study of tl 895 a bruton s tyrosine kinase inhibitor btki added to ruxolitinib rux in patients pts with myelofibrosis mf |
| url | http://journals.lww.com/10.1097/01.HS9.0000975544.01102.10 |
| work_keys_str_mv | AT francescapalandri pb2198trialinprogressanopenlabelglobalmulticenterphase1b2studyoftl895abrutonstyrosinekinaseinhibitorbtkiaddedtoruxolitinibruxinpatientsptswithmyelofibrosismf AT stefaniegropper pb2198trialinprogressanopenlabelglobalmulticenterphase1b2studyoftl895abrutonstyrosinekinaseinhibitorbtkiaddedtoruxolitinibruxinpatientsptswithmyelofibrosismf AT michaelloschi pb2198trialinprogressanopenlabelglobalmulticenterphase1b2studyoftl895abrutonstyrosinekinaseinhibitorbtkiaddedtoruxolitinibruxinpatientsptswithmyelofibrosismf AT marcelobellesso pb2198trialinprogressanopenlabelglobalmulticenterphase1b2studyoftl895abrutonstyrosinekinaseinhibitorbtkiaddedtoruxolitinibruxinpatientsptswithmyelofibrosismf AT sebastiangrosicki pb2198trialinprogressanopenlabelglobalmulticenterphase1b2studyoftl895abrutonstyrosinekinaseinhibitorbtkiaddedtoruxolitinibruxinpatientsptswithmyelofibrosismf AT pilargiraldo pb2198trialinprogressanopenlabelglobalmulticenterphase1b2studyoftl895abrutonstyrosinekinaseinhibitorbtkiaddedtoruxolitinibruxinpatientsptswithmyelofibrosismf AT claireharrison pb2198trialinprogressanopenlabelglobalmulticenterphase1b2studyoftl895abrutonstyrosinekinaseinhibitorbtkiaddedtoruxolitinibruxinpatientsptswithmyelofibrosismf AT tracyclevenger pb2198trialinprogressanopenlabelglobalmulticenterphase1b2studyoftl895abrutonstyrosinekinaseinhibitorbtkiaddedtoruxolitinibruxinpatientsptswithmyelofibrosismf AT nikkistuart pb2198trialinprogressanopenlabelglobalmulticenterphase1b2studyoftl895abrutonstyrosinekinaseinhibitorbtkiaddedtoruxolitinibruxinpatientsptswithmyelofibrosismf AT hopeqamoos pb2198trialinprogressanopenlabelglobalmulticenterphase1b2studyoftl895abrutonstyrosinekinaseinhibitorbtkiaddedtoruxolitinibruxinpatientsptswithmyelofibrosismf AT gregoryvosganian pb2198trialinprogressanopenlabelglobalmulticenterphase1b2studyoftl895abrutonstyrosinekinaseinhibitorbtkiaddedtoruxolitinibruxinpatientsptswithmyelofibrosismf AT wayneprothbaum pb2198trialinprogressanopenlabelglobalmulticenterphase1b2studyoftl895abrutonstyrosinekinaseinhibitorbtkiaddedtoruxolitinibruxinpatientsptswithmyelofibrosismf AT srdanverstovsek pb2198trialinprogressanopenlabelglobalmulticenterphase1b2studyoftl895abrutonstyrosinekinaseinhibitorbtkiaddedtoruxolitinibruxinpatientsptswithmyelofibrosismf AT pankitvachhani pb2198trialinprogressanopenlabelglobalmulticenterphase1b2studyoftl895abrutonstyrosinekinaseinhibitorbtkiaddedtoruxolitinibruxinpatientsptswithmyelofibrosismf |